← Compound index
COMPOUND RECORD / KEMANTANE

KemantaneКемантан

A synthetic adamantane compound studied in Russian immune research, including historical clinical reports.

Immune Function
Source linked

What the studies found

Study involving people · 1990

Kemantane in recurrent aphthous stomatitis

Lesion healing and remission
Earlier epithelialization and longer remissions reported in fibrous and scarring forms.No numerical differences or comparator denominators available.

The authors reported faster lesion healing and longer remission in fibrous or scarring recurrent aphthous stomatitis. No effect size or time-to-healing figures appear in the abstract.

Study notes · methods, sources and limitations

Participants or model 30 Kemantane-treated patients with severe recurrent aphthous stomatitis.

Design Clinical and blood-marker assessments in 30 treated patients with severe recurrent aphthous stomatitis.

Important limitations

  • The abstract does not give the dose, schedule, comparator size, allocation methods or adverse-event counts.
  • Dose, course length, relapse duration and harms require the full article.

Stomatologiia (Mosk). 1990;69(1):31–33. · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Comparison in people · 1991

Fourteen treated patients showed changes in immune markers

T-cell count and blast formation
Increases reported in the 14 treated patients.Unchanged or declining measures reported in untreated patients.
T-cell functional activity
Upward trend reported in treated patients.

In the 14 treated patients, the authors reported increased T-cell counts and lymphocyte blast formation. T-cell functional activity showed a favorable trend. Untreated patients’ immune measures were unchanged or tended to decline.

Study notes · methods, sources and limitations

Participants or model 219 observed patients, 136 with and 83 without respiratory viral infection. Fourteen patients received Kemantane.

Design Pulmonary tuberculosis observational cohort (219). Of 136 with respiratory viral infection, 14 received Kemantane.

Important limitations

  • Treatment selection, dose, comparator denominator and the numerical immune effects require the full text. The 19.1% clinical aggravation figure describes the association with infection. A Kemantane effect on tuberculosis outcomes was not quantified.
  • The 19.1% aggravation figure concerned viral infection. It was not a between-arm estimate for Kemantane.

Probl Tuberk. 1991;(6):23–26. · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Study involving people · 1991

Clinical pharmacokinetics of Kemantane in bronchial disease

Parent compound in blood
Little or no detectable parent Kemantane. The authors evaluated exposure through its major active metabolite.

Gas–liquid chromatography detected little parent compound in blood. The authors attributed this to first-pass metabolism and characterized exposure using the principal active metabolite.

Study notes · methods, sources and limitations

Participants or model Patients with bronchial disease. Enrollment was not stated in the abstract.

Design Gas–liquid chromatography in patients with bronchial disease.

Important limitations

  • The abstract does not provide the dose, sampling schedule or numerical pharmacokinetic estimates. This report assesses exposure.
  • The abstract provides no numerical estimates, dose, sampling schedule or group sizes.

Farmakol Toksikol. 1991;54(1):57–59. · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Kemantane

Names in this research collection

ADK-412 · Kemantan

Research background

An adamantane preparation used as an immune-pharmacology comparator in the historical ADK program. This entry documents those experiments; formulation-specific clinical evidence remains unreviewed.

Compound class
Experimental adamantane / analogue
Research collection
Actoprotection & occupational pharmacology · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Human efficacy results unavailable

Study methods

Source-specific animal, chemistry, patent or dissertation evidence

Independent replication

Independent replication not established; translations are not separate experiments

Source access

Access and review depth appear with each linked record

Safety evidence

Human safety and interactions not established; animal activity is not a safe-use recommendation

Open a topic for the evidence assessment.

More findings, background and history

Chlodantane, Cyclontane and the ADK research program ↗

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

1990 · SU1586711A1 · Kemantane: historical immunostimulatory-use disclosureUse · Walking distance reportedly increased from 100–150 m to 500–700 m

Reported findings

Case reports describe improved walking, ulcer healing and a lymphocyte marker, with no reliable treatment-rate estimate.

Peripheral-vascular case
Walking distance reportedly increased from 100–150 m to 500–700 mAfter a two-week course; one-year observation mentionedOne patient; concurrent care and standardized testing not established
Ulcer case
Foot ulcers reportedly healed during treatmentTwo weeks; favorable one-year observation describedAnother individual case, not a controlled ulcer-healing rate
All reported results, comparisons and limitations →

Use. The Soviet publication describes Kemantane in an immunostimulatory application.

Historical disclosure is not a modern controlled clinical trial and does not establish autoimmune benefit.

Publication
SU1586711A1 ↗ · 1990-08-23
Earliest priority / filing
1977-05-13 / 1977-05-13
Original applicant / assignee
Институт фармакологии АМН СССР
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
20708410 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Immunostimulating agent "kemantan"

Inventors: Нинель Григорьевна Арцимович; Татьяна Александровна Фадеева; Юлия Анатольевна Шалыминова; Татьяна Евгеньевна Захарова; Ираида Андреевна Асташина; Ольга Васильевна Щербакова; Михаил Исаевич Шмарьян; Александр Борисович Вайншток; Нина Васильевна Климова; Лидия Николаевна Лаврова; Александр Петрович Сколдинов.

SU1586711A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Study involving people · 1990

Kemantane in recurrent aphthous stomatitis

The authors reported faster lesion healing and longer remission in fibrous or scarring recurrent aphthous stomatitis. No effect size or time-to-healing figures appear in the abstract.

Study notes and original source
1990Human study · design details unresolvedEnglish abstract

Kemantane in recurrent aphthous stomatitis

N. V. Terekhova, V. V. Khazanova, E. A. Zemskaia, et al. · Stomatologiia (Mosk). 1990;69(1):31–33.

The authors reported faster lesion healing and longer remission in fibrous or scarring recurrent aphthous stomatitis. No effect size or time-to-healing figures appear in the abstract.

Results and tables

Reported findings and study design

Findings described in words

Clinical and blood-marker assessments in 30 treated patients with severe recurrent aphthous stomatitis.

Population or model 30 Kemantane-treated patients with severe recurrent aphthous stomatitis.

Results · Indexed English abstract of the original Russian journal report.
MeasureResultComparison, timing and statistics
Lesion healing and remissionEarlier epithelialization and longer remissions reported in fibrous and scarring forms.No numerical differences or comparator denominators available.

Dose, course length, relapse duration and harms require the full article.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
30 Kemantane-treated patients with severe recurrent aphthous stomatitis.
Source reviewed
Indexed English abstract of the original Russian journal report.
Study limitations
  • The abstract does not give the dose, schedule, comparator size, allocation methods or adverse-event counts.

Reviewed 2026-11-14.

Read the source ↗

Comparison in people · 1991

Kemantane in tuberculosis patients with intercurrent respiratory viral infection

In the 14 treated patients, the authors reported increased T-cell counts and lymphocyte blast formation. T-cell functional activity showed a favorable trend. Untreated patients’ immune measures were unchanged or tended to decline.

Study notes and original source
1991Human comparative studyEnglish abstract

Kemantane in tuberculosis patients with intercurrent respiratory viral infection

N. V. Kossii, I. S. Khomenko, V. Ia. Gergert · Probl Tuberk. 1991;(6):23–26.

In the 14 treated patients, the authors reported increased T-cell counts and lymphocyte blast formation. T-cell functional activity showed a favorable trend. Untreated patients’ immune measures were unchanged or tended to decline.

Results and tables

Reported findings and study design

Findings described in words

Pulmonary tuberculosis observational cohort (219). Of 136 with respiratory viral infection, 14 received Kemantane.

Population or model 219 observed patients, 136 with and 83 without respiratory viral infection. Fourteen patients received Kemantane.

Results · Indexed English abstract of the original Russian journal report.
MeasureResultComparison, timing and statistics
T-cell count and blast formationIncreases reported in the 14 treated patients.Unchanged or declining measures reported in untreated patients.
T-cell functional activityUpward trend reported in treated patients.

The 19.1% aggravation figure concerned viral infection. It was not a between-arm estimate for Kemantane.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
219 observed patients, 136 with and 83 without respiratory viral infection. Fourteen patients received Kemantane.
Source reviewed
Indexed English abstract of the original Russian journal report.
Study limitations
  • Treatment selection, dose, comparator denominator and the numerical immune effects require the full text.
  • The 19.1% clinical aggravation figure describes the association with infection. A Kemantane effect on tuberculosis outcomes was not quantified.

Reviewed 2026-11-14.

Read the source ↗

Study involving people · 1991

Clinical pharmacokinetics of Kemantane in bronchial disease

Gas–liquid chromatography detected little parent compound in blood. The authors attributed this to first-pass metabolism and characterized exposure using the principal active metabolite.

Study notes and original source
1991Human study · design details unresolvedEnglish abstract

Clinical pharmacokinetics of Kemantane in bronchial disease

S. S. Boiko, V. P. Zherdev, N. A. Kisliak · Farmakol Toksikol. 1991;54(1):57–59.

Gas–liquid chromatography detected little parent compound in blood. The authors attributed this to first-pass metabolism and characterized exposure using the principal active metabolite.

Results and tables

Reported findings and study design

Findings described in words

Gas–liquid chromatography in patients with bronchial disease.

Population or model Patients with bronchial disease. Enrollment was not stated in the abstract.

Results · Indexed English abstract of the original Russian journal report.
MeasureResultComparison, timing and statistics
Parent compound in bloodLittle or no detectable parent Kemantane. The authors evaluated exposure through its major active metabolite.

The abstract provides no numerical estimates, dose, sampling schedule or group sizes.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
Patients with bronchial disease. Enrollment was not stated in the abstract.
Source reviewed
Indexed English abstract of the original Russian journal report.
Study limitations
  • The abstract does not provide the dose, sampling schedule or numerical pharmacokinetic estimates. This report assesses exposure.

Reviewed 2026-11-14.

Read the source ↗

Experiment described in a patent · 1990

Kemantane: historical immunostimulatory-use disclosure — SU1586711A1

Case reports describe improved walking, ulcer healing and a lymphocyte marker, with no reliable treatment-rate estimate.

Peripheral-vascular case · Walking distance reportedly increased from 100–150 m to 500–700 m · One patient; concurrent care and standardized testing not established · After a two-week course; one-year observation mentioned

Study notes and original source
1990Patent / reported experimentsFull text available

Kemantane: historical immunostimulatory-use disclosure — SU1586711A1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Нинель Григорьевна Арцимович, Татьяна Александровна Фадеева, Юлия Анатольевна Шалыминова, Татьяна Евгеньевна Захарова, Ираида Андреевна Асташина, Ольга Васильевна Щербакова, Михаил Исаевич Шмарьян, Александр Борисович Вайншток, Нина Васильевна Климова, Лидия Николаевна Лаврова, Александр Петрович Сколдинов · SU1586711A1 · patent family 20708410

Case reports describe improved walking, ulcer healing and a lymphocyte marker, with no reliable treatment-rate estimate.

Results and tables

Reported patent results

Reported findings

Case reports describe improved walking, ulcer healing and a lymphocyte marker, with no reliable treatment-rate estimate.

Kemantane patent describes selected clinical cases of vascular and respiratory disease without a controlled cohort.

Population or model Kemantane patent describes selected clinical cases of vascular and respiratory disease without a controlled cohort.

Results · Clinical Examples 1–3; case observations distinguished from general recommendations.
MeasureResultComparison, timing and statistics
Peripheral-vascular caseWalking distance reportedly increased from 100–150 m to 500–700 mOne patient; concurrent care and standardized testing not established · After a two-week course; one-year observation mentioned
Ulcer caseFoot ulcers reportedly healed during treatmentAnother individual case, not a controlled ulcer-healing rate · Two weeks; favorable one-year observation described
Chronic-bronchitis caseE-rosette marker 12% → 50%, alongside improved symptomsSingle-patient immune-marker change · Around day 10

Selected cases and marker changes do not establish general immune benefit, autoimmune disease control, clinical efficacy or long-term safety.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Kemantane patent describes selected clinical cases of vascular and respiratory disease without a controlled cohort.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • Historical disclosure is not a modern controlled clinical trial and does not establish autoimmune benefit.
  • Selected cases and marker changes do not establish general immune benefit, autoimmune disease control, clinical efficacy or long-term safety.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Animal research · Year unconfirmed

Role of neurotropic adamantane-containing compounds in the regulation of immunity

This preparation is included in an immune-regulation dissertation trail. A reliable preparation-specific effect estimate has not been extracted; findings emphasized for ADK-910 cannot be assigned to it.

Study notes and original source
Year unconfirmedAnimal / experimentalRussian-language source

Role of neurotropic adamantane-containing compounds in the regulation of immunity

· Dissertation; OCR reproduction

Format: Dissertation abstract transcription · Reviewed: See scope

· Dissertation author’s abstract; third-party Russian transcription

The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.

Population / setting
Multiple mouse strains and laboratory immune assays
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata.
  • Immune and colony assays do not demonstrate better health, infection prevention or long-term stem-cell expansion in people.

Reviewed 2026-10-03.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗